EQUILLIUM INC

EQ refers to the common stock of Equillium, Inc., a clinical-stage biotechnology company. It trades on the Nasdaq Capital Market under the ticker EQ. The stock represents an ownership stake in the company, whose work centers on developing therapies for severe autoimmune and inflammatory diseases. Because Equillium is a small-cap biotech, EQ's price can be sensitive to clinical trial updates, regulatory milestones, and financing news.

Equillium, Inc. is a biotechnology company focused on discovering and developing treatments for autoimmune and inflammatory disorders. Its pipeline includes product candidates designed to target specific immune pathways, such as itolizumab, which is being studied in conditions like lupus nephritis and ulcerative colitis. The company typically works through licensing arrangements and clinical trials, meaning its progress depends on trial results and regulatory outcomes rather than commercial sales.

Recent performance for EQ can change quickly because Equillium is a clinical-stage biotech with no approved products generating revenue. Rather than relying on stale figures, check the latest EQ quote and performance chart on this page for current price, recent percentage moves, and volume. Those data reflect the most up-to-date market reaction to company news, sector trends, and broader market conditions.

EQ carries risks common to clinical-stage biotechs, including the possibility that drug candidates fail in trials, regulatory delays, and the need to raise additional capital, which can dilute existing shareholders. As a small-cap with no product revenue, EQ may be more volatile than larger healthcare companies. Investors should review Equillium's SEC filings, especially risk factors, cash position, and upcoming catalysts.

Valuing EQ is different from valuing a profitable company because Equillium has no product revenue. Traditional metrics like the P/E ratio are often not meaningful. Instead, analysts may use cash balances, projected cash burn, pipeline progress, and comparable biotech transactions. The most reliable current valuation figures for EQ are the market cap, enterprise value, and price-to-book ratios shown in the data panel on this page.

The latest EQ stock price is displayed at the top of this stock detail page, along with the day's change, volume, and other real-time or delayed market data. For the most current quote, refresh the page or check a brokerage platform or market data provider. Since EQ is a small-cap biotech, prices can move quickly, so relying on up-to-date figures is important.